CliffBio
small molecule

BAQSIMI

GLUCAGON

Loss of exclusivitySeptember 2039latest FDA-listed patent expiry
CompanyAmphastar Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameBAQSIMI
Active ingredientGLUCAGON
Strength3MG
Dosage formPOWDER
RouteNASAL
ModalitySmall molecule
FDA approvalJuly 2019
Marketing statusRX

Listed patents

PatentExpiresType
10765602September 2039product
10213487February 2036product
12370241February 2036product

Regulatory exclusivity

CodeExpires
NPPMarch 2028

More from Amphastar Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.